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The role of viral infections, such as herpes simplex virus (HSV) infection, in the pathogenesis of Behc¸et’s disease (BD) has been
investigated for many years. HSV has been detected in peripheral blood leukocytes, saliva, and genital ulcers of patients with
BD. Various cell adhesion molecules on cultured endothelial cells have been induced by HSV in a TNF-𝛼 dependent manner.
In addition, a BD-like animal model was developed by inoculating ICR mouse earlobes with HSV, and antiviral treatment was
effective in improving BD-like symptoms in this model. Still, there are several incompletely characterized proteins that possess
antiviral properties and are being investigated as mediators of viral infection-related chronic inflammatory reactions. Although the
role of HSV in the pathogenesis of BD remains to be fully established, recent research findings regarding HSV in BD have expanded
our understanding of the disease and will hopefully lead to the development of more effective therapeutic agents in the near future.
1. Introduction: Historical Background
The role of viral infection in the pathogenesis of Behc¸et’s
disease (BD) was first suggested by Huˆlusi Behc¸et, a Turkish
dermatologist, in 1937 [1]. Early publications reported iso-
lating virus from the ocular fluid, eye, and brain of patients
with BD, but these findings were not initially confirmed
by others [2–4]. With more recent advances in virology
and immunology, DNA has been isolated in BD patients
from various types of viruses, including herpes simplex virus
(HSV), varicella zoster virus, cytomegalovirus, Epstein-Barr
virus, human herpes virus 6 and 7, hepatitis virus, human
immunodeficiency virus, and parvovirus B19 [5, 6]. Among
these viruses, HSV is the leading candidate for playing
a potentially key role in the pathogenesis of BD. In situ
DNA-RNA hybridization techniques have demonstrated the
presence of part of the HSV-1 genome in peripheral blood
mononuclear cells of patients with BD [7]. Polymerase chain
reaction (PCR) studies have confirmed the presence of a
211-base pair (bp) HSV-1 DNA fragment in the peripheral
blood leukocytes of patients with BD [8] and demonstrated
significantly greater quantities of HSV-1 DNA in the saliva,
intestinal ulcers, and genital ulcers in BD patients than con-
trols [9]. In addition, a BD-like animal model was developed
by inoculating ICR mice with HSV [10, 11] and antiviral
treatment was effective in improving BD-like symptoms in
40% of famciclovir treated BD mice [12].
Despite the aforementioned observations, the role ofHSV
in the pathogenesis of BD has not been firmly established,
and the function of innate immunity and immunization
treatment options remain to be elucidated. This review will
discuss the current state of our knowledge regarding the role
of HSV in BD and explore the possible future implications of
this knowledge for the diagnosis and treatment of the disease.
2 Genetics Research International
2. Clinical Evidence Supporting the Role of
HSV Infection and Detection of HSV in the
Mucocutaneous Lesions in Behçet’s Disease
BD is a recurrent, multisystemic inflammatory disease typi-
cally characterized by recurring oral aphthous ulcers, genital
ulcers, ocular lesions, and cutaneous lesions and occasional
articular, urogenital, vascular, gastrointestinal, and neurolog-
ical involvement [13]. Oral ulcerations, the most common
clinical manifestation of BD, include three patterns: minor
ulcers, major ulcers, or herpetiformulcers.The least common
variety of oral aphthosis is herpetiform ulceration, which
consists of numerous (up to 100) 2-3mm lesions distributed
throughout the oral cavity [14]. In common herpetic ulcers
caused by HSV, the viral blisters quickly rupture, resulting
in multiple small ulcers that often coalesce to form larger
irregular ulcers [15].The clinical similarities between herpeti-
form ulcers in BD and ulcers due to HSV infection suggest
an etiologic role of HSV in BD and several studies have
attempted to isolate HSV from the oral ulcers of patients
with BD. HSV-1 DNA fragments have been detected by
PCR [8] or in situ hybridization [7] in significant numbers
in the peripheral blood leukocytes of patients with BD;
however, viral DNA has not been detected in biopsy samples
taken from oral ulcers, even in the presence of high anti-
HSV-1 antibody concentrations in the peripheral blood of
BD patients [8, 16]. The inability to detect viral DNA in
tissue could be due to the viral DNA being present in small
fragments rather than as an intact viral genome [8]. To further
explore the role of HSV in the pathogenesis of BD, our group
evaluated the presence of HSV DNA in saliva samples from
66 patients with the disease. The 289-bp band specific for
HSVDNAwas detected in DNA preparations from the saliva
of 26 (39.4%) patients [9].
Although less common than oral lesions, patients with
BD also often have genital lesions, which are characterized
by ulcers. Clinically differentiating BD genital ulcers from
HSV-induced ulcers (the most common type of genital ulcer
in developed countries) is often difficult [17]. The clinical
similarities suggest that HSV has a pathogenic role in the
development of genital ulcers in BD. Moreover, HSV-1 DNA
has been identified by PCR in biopsy samples obtained from
genital ulcers of BD patients but not in biopsies from healthy
controls [18].
Various cutaneous manifestations may be found in
BD, including an erythema multiforme-like rash, which
accounts for approximately 5% of BD skin lesions [19].
Conventional erythema multiforme is a hypersensitivity
reaction associated with certain infections and medications.
It can involve the oral, ocular, genital, upper respiratory,
or pharyngeal mucosa [20]. HSV is the most common
precipitating agent. HSV-associated erythema multiforme
is usually limited to the oral mucosa, more specifically,
the labial and buccal mucosa, nonattached gingivae, and
vermillion lip [21]. Except for the occurrence of a prodromal
episode of recurrent herpes infection in HSV-associated
erythema multiforme, it is often difficult to distinguish this
condition from the erythema multiforme-like lesions in
BD. Because of this, many diagnostic criteria for BD do not
include erythema multiforme-like rash as a disease-defining
skin manifestation [22, 23]. Till now direct detection of
HSV DNA from erythema multiforme-like lesions in BD
has not been reported although the presence of HSV-1
and HSV-2 genomes in skin lesion from patients with
BD was infrequently reported [24]. However, the clinical
similarities between HSV-associated erythema multiforme
and erythema multiforme-like lesions in BD are further
evidence supporting an association between HSV and BD.
3. The Effect of HSV Infection on the
Expression of Cell Adhesion Molecules in
Cultured Human Dermal Microvascular
Endothelial Cells
Cell-mediated immune responses to HSV have been impli-
cated in the pathogenesis of various inflammatory diseases,
including BD. HSV DNA and viral antigens are frequently
detected in skin lesions of HSV-associated erythema multi-
forme [25], but it is unclear whether the pathologic changes
in skin lesions are caused by the virus itself or by a sec-
ondary immunological reaction to a viral antigen. In vitro
studies of cultured human dermal microvascular endothe-
lial cells (HDMECs) have demonstrated that exposure to
HSV-1 increased binding of T cells to HDMECs [26] and
increased expression of cell adhesion molecules, such as
CD54 (intercellular adhesionmolecule-1 [ICAM-1]), vascular
adhesion molecule 1 (VCAM-1), and E-selectin by HDMECs
[26]. Similarly, incubation of HSV-infected peripheral blood
mononuclear cells with uninfected HDMECs induced upreg-
ulation of CD54 and major histocompatibility complex class
I molecules on HDMECs [27]. The binding of T cells to
HDMECs was inhibited by anti-CD54, anti-interleukin (IL)-
1𝛼, or anti-tumour necrosis factor (TNF)-𝛼 antibody [26].
These in vitro data suggest that IL-1𝛼 or TNF-𝛼 produced by
HSV-infected HDMEC may function in the immunopatho-
genesis of BD. Thalidomide is a TNF-𝛼 inhibitor that is
effective in both BD patients [28] and a BD-like mouse
model [29]. The TNF-𝛼 blockers infliximab and etanercept
have both been shown to reduce serum concentrations of
soluble ICAM-1 and E-selectin in patients with arthritis [30,
31]. As well, a synthesized pyridine compound derivative
(SK94) downregulated E-selectin, VCAM-1, and ICAM-1 in
the HSV-induced BDmousemodel [32]. Together with TNF-
𝛼 inhibitors, targeting HSV-induced cell adhesion molecules
on endothelial cells may thus be a promising therapeutic
strategy for BD.
4. Behçet’s Disease-Like Symptoms Induced by
HSV in ICR Mice
To further explore the role of HSV in the pathogenesis
of BD, we developed an HSV-induced BD mouse model.
After inoculation of the scratched earlobe of 258 ICR
mice with HSV type 1, 77 (29.8%) mice exhibited BD-
like syndrome, defined by the presence of two or more
BD symptoms. These symptoms and their overall frequency
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were as follows: skin ulcers (57.1%); eye symptoms (39.0%);
partial hair loss (33.8%); genital ulcers (19.5%); bullae (11.7%);
arthritis (5.2%); gastrointestinal ulcer (5.2%); and tongue
ulcers (3.9%). The ulcers, uveitis, and arthritis were clinically
similar to those seen in patients with BD. Skin lesions
stained with hematoxylin and eosin showed accumulations
of perivascular inflammatory cells, and vasculitis was com-
mon in the intestinal, oral, ear lobe, and genital epithelial
lesions [11]. More recently, 18F-fluorodeoxyglucose positron
emission tomography showed the presence of symptomatic
and asymptomatic knee joint inflammation in BD mice
[33]. Although BD-like symptoms have been induced by
inoculating the scratched earlobe of mice, direct injection of
HSV in the perioral area, tongue, cornea, peritoneum, and
footpad has not produced BD-like symptoms (unpublished
data). HSV-induced BD-like symptoms are dependent on the
species of mice: symptoms have been observed in 40%–50%
of HSV-inoculated B10.BR, B10.RIII, and C57BL/6 mice but
only 2% of C3H/He strain mice [34]. The function of HLA-
G (Qa-2 in mice), which is immunosuppressive gene, was
also decreased in HSV-induced BD mice [35]. The species-
specificity and inherent abnormality of HLA molecules in
this mice model are also similar to the presence of genetic
predisposition in BD patients.
5. Expression of Th2 Cytokine Decreases the
Development of and Improves Behçet’s
Disease-Like Symptoms Induced by Herpes
Simplex Virus in Mice
Although BD-like symptoms have been induced by HSV
inoculation of mice, viral infection alone is insufficient to
explain the pathogenesis of BD, as no more than half of inoc-
ulated mice develop BD symptoms [11, 34]. To study the pos-
sible role of immunologic abnormalities in the development
of BD-like symptoms induced by HSV inoculation of ICR
mice,macrophageswere depleted by intraperitoneal injection
of liposome-encapsulated clodronate [36]. The incidence of
BD-like symptoms was 28% in mice injected with HSV
alone and 0% in mice that underwent macrophage depletion
plus HSV inoculation. Macrophage depletion correlated with
increased IL-4 expression in the mice spleens. When type
2 T helper cell (Th2) adjuvant ovalbumin (OVA)-alum was
injected intomice with BD-like symptoms, cytokine IL-4 was
upregulated and cutaneous symptoms improved. Adoptive
transfer with splenocytes from OVA-alum-injected normal
healthy mice into BD mice also resulted in improvement.
These findings thereby suggest that upregulatedTh2 cytokine
expression can prevent or improve at least some BD-like
symptoms. Nagafuchi et al. [37] also reported Th1 cells and
the Th1-associated cytokines may play a detrimental role in
the development of skin lesions in patients with BD.
6. Learning from HSV-Infected Mice as a
Model of Behçet’s Disease
Most animal models of disease are not perfectly matched to
their corresponding human disease, but they are often the
most appropriate research tool. Furthermore, the complexity
of BD makes it difficult to develop a single experimental
animal model to understand the mechanisms responsible for
all BD symptoms. Currently, the HSV-induced BD mouse
model is the model that most closely mimics the symptoms,
histological characteristics, immunological abnormalities,
and responses to therapeutic modalities of patients with BD.
This mouse model has been a useful tool for the study of
BD pathogenesis and pharmacotherapy. Since the successful
development of an HSV-induced BD mouse model was first
reported in 1998 [11], over 20 papers using this model have
been published. These papers have involved such topics as
immunological abnormalities, including major histocom-
patibility (MHC) relevance [34, 35], Th1/Th2 balance [36],
and CD4+CD25+Foxp3+ regulatory T cells [38]; therapeutic
targets, such as TNF𝛼 [39], IL-6 [40], and IL-17 [40]; and
conventional and potential therapies involving colchicines
[41, 42], thalidomide [29], famciclovir [34], gemcitabine
(2󸀠,2󸀠-difluorodeoxycytidine) [43], IL-4 DNA vector [44],
and vitamin D3 [45].
7. Innate Immunity and Tripartite Motif-
Containing Proteins in Viral Infection
Tripartite motif-containing (TRIM) proteins, a family of
RING domain-containing E3 ligases, play diverse functions
in cell biology and immunity [46]. Several TRIM proteins
exhibit direct antiviral activity, by restricting various stages
of the viral replication cycle [47]. Some TRIM proteins also
regulate signalling of immune pathways mediated by pattern
recognition receptors [48].With recent elucidation of the role
of TRIM proteins as viral restriction factors or regulators of
the viral RNA/DNA sensing pathway and the inflammasome,
the role of TRIM proteins as key molecules in antiviral
immunity has become increasingly apparent [47, 48]. TRIM
proteins contribute to the regulation of immune responses,
including the production of type I interferons and proinflam-
matory cytokines such as interleukin-1𝛽, and they have been
reported to have pathogenic roles in numerous autoimmune
diseases, including systemic lupus erythematosus, gout, type
2 diabetes, rheumatoid arthritis, and Crohn’s disease [47, 49,
50].
Because of the role of TRIM proteins in antiviral immu-
nity, pattern recognition receptor signalling, inflammasome
activation, and autoimmunity, it has recently been suggested
that these proteins may contribute to the pathogenesis of BD.
A single nucleotide polymorphisms study published in 2010
demonstrated that TRIM39 was independently associated
with BD, suggesting that itmay contribute to the pathogenesis
of the disease [51]. TRIM39R (although not TRIM39B) was
subsequently reported to be related to the regulation of the
type I interferon response [52].
TRIM19, which is also known as the promyelocytic
leukaemia (PML) protein, organizes PML nuclear bodies,
which function in antiviral immunity [53]. The genomes
of HSV-1 and human cytomegalovirus are both subject to
transcriptional repression bymechanisms involvingPMLand
nuclear body components [54]; these are important innate
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antiviral defence mechanisms. TRIM19 enhances interferon-
𝛾-mediated antiviral gene expression [55], and its depletion
has led to increased replication of HSV-1 in previous studies
[53, 54]. As HSV infection appears to play an important role
in the pathogenesis of BD and TRIM19 functions in innate
defence mechanisms against HSV, this suggests that TRIM19
may contribute to the development of BD.
Several other TRIM proteins also possess antiviral prop-
erties and are being investigated as potential mediators of
autoimmune or chronic inflammatory disorders [46–48].
However, studies regarding the relationship between TRIM
proteins in BD are rare. Since TRIM proteins have the poten-
tial to function as a potent cellular detection mechanism and
can allow cells to stimulate broad-spectrum immunity [56],
they may be candidate molecules for connecting the innate
immune system to the pathogenesis of BD.Therefore, further
investigations to reveal the role of TRIMproteins in BDmight
aid in further elucidating the pathogenesis of this disease.
8. Therapeutic Efficacy of HSV-Targeted
Treatments in BD Patients and the BD
Mouse Model
There is currently no single curative therapeutic agent for
BD. Present treatment of BD is empirical and focuses on
symptom relief, not a complete cure. The treatment generally
depends on the clinical manifestations of each patient and
is thus primarily patient-specific [57–60]. Although various
therapeutic agents have been used for BD, the treatment
results vary widely between agents and individuals, and the
results are far from optimal [60].
As HSV has been substantially implicated in the patho-
genesis of BD [7–11], most strategies have been centred
on treating the HSV infection itself or blocking the HSV-
related immunologic pathways. Although treatment with
acyclovir failed to reduce the frequency and severity of
orogenital ulceration or other clinical manifestations in BD
patients [61], treatment with famciclovir, a prodrug form of
penciclovir that inhibits viral DNA polymerase, was effective
in improvingBD-like symptoms andpreventing relapse in the
mouse model of BD [34].
TNF-𝛼, a representative proinflammatory cytokine, is
primarily produced by T cells, polymorphonuclear cells,
dendritic cells, and macrophages [62]. In macrophages,
production of TNF-𝛼 can be induced by physical, chemical,
and biologic stimuli, including ischemia, trauma, irradiation,
tumour cells, complement, and various other cytokines [39].
The TNF-𝛼 signalling pathway can also be induced by
bacterial and viral infections. As viral infection appears to
be a triggering factor for BD, studies focusing on reducing
or blocking TNF-𝛼 signalling have been performed. Injecting
TNF-𝛼 small interfering RNA or anti-TNF-𝛼 blockades
(infliximab or etanercept) inhibited TNF-𝛼 gene expression
and improved symptoms in a BD mouse model [39]. Syn-
thesized pyridine compound derivatives (SK94 and SK126)
are also potential therapeutic candidates for BD, as they have
been shown to downregulate cell adhesion molecules and
TNF-𝛼, and ameliorate symptoms in the BD mouse model
[32].
Investigations continue to be conducted to more fully
elucidate the pathogenesis of BD and to develop novel
therapeutic agents. Peptides such asHsp-65/60 are now being
considered as possible new therapeutic targets for patients
with BD [63]. Further investigations, including clinical trials
in humans, are required to validate the effectiveness and
safety of candidate agents. Additionally, more in-depth stud-
ies are required to investigate the role of immune reactions
in BD, including not only adaptive responses but also innate
immune reactions, such as those related to TRIM proteins.
9. Conclusion
The exact pathogenesis of BD remains elusive, although
research continues to increase our understanding of the
complex pathogenetic mechanisms of the disease. Infectious
agents, such as HSV and Streptococcus sanguinis, have long
been postulated as possible environmental triggers of BD,
and the role of HSV continues to be a main focus of BD
research. Clinical observations and the detection of HSV
DNA in saliva and genital ulcers of BD patients prompted us
to investigate the effects of HSV in BD in vitro and in vivo.
Establishing a BDmouse model using HSV inoculation facil-
itated our investigations of the pathogenesis of BD and, more
importantly, the therapeutic efficacy of emerging medicines.
As current treatment options for BD are limited and often
unsatisfactory, it is hoped that recent research findings will
lead to the development of successful therapeutic strategies
for BD in the near future.
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